rss
Ann Rheum Dis 2010;69:263-269 doi:10.1136/ard.2008.103663
  • Basic and translational research
  • Extended report

Circulating cytokines in active polymyalgia rheumatica

  1. L Alvarez-Rodríguez1,
  2. M Lopez-Hoyos2,
  3. C Mata3,
  4. M Jose Marin2,
  5. J Calvo-Alen3,
  6. R Blanco1,
  7. E Aurrecoechea3,
  8. M Ruiz-Soto1,
  9. V M Martínez-Taboada1
  1. 1
    Servicio de Reumatología, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
  2. 2
    Servicio de Inmunología, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Santander, Spain
  3. 3
    Fundación Marqués de Valdecilla-IFIMAV, Sección de Reumatología, Hospital de Sierrallana, Torrelavega, Cantabria, Spain
  1. Correspondence to Dr V M Martínez-Taboada, Rheumatology Division, Hospital Universitario Marqués de Valdecilla, Facultad de Medicina, Universidad de Cantabria, Avda Valdecilla s/n 39008, Santander, Spain; vmartinezt{at}medynet.com
  • Accepted 6 February 2009
  • Published Online First 1 March 2009

Abstract

Objective: To characterise the circulating cytokine profile and the cellular source of circulating cytokines in polymyalgia rheumatica (PMR).

Methods: The study included 34 patients with active untreated PMR and 17 age-matched healthy controls (HC). Circulating cytokines were measured by cytometric bead array and ELISA. Intracellular cytokines were assessed in CD3+ and CD14+ cells by flow cytometry. Cytokines in cell culture supernatants were also determined after polyclonal stimulation of patients’ peripheral blood mononuclear cells.

Results: Circulating levels of interleukin-6 (IL6) were significantly higher in subjects with active PMR than in HC. Corticosteroid (CS) treatment was followed by a decrease in the level of IL6. Intracellular cytokine staining showed that circulating monocytes did not produce higher amounts of proinflammatory cytokines in patients with PMR than in HC. There was a discordance between serum levels and cytokine-producing monocyte and T cells, and it was not possible to demonstrate a Th1 bias in the peripheral compartment.

Conclusions: Active PMR is characterised by increased serum levels of IL6, but not of other proinflammatory cytokines, that are rapidly suppressed by CS treatment. As circulating monocytes do not show increased production of proinflammatory cytokines, IL6 may be mainly produced in the inflamed tissue. A study of the circulating cytokine profile and its cellular source may provide a clue to new therapeutic options.

Footnotes

  • Funding This work was supported by grants from Fondo de Investigación Sanitaria (05/0475), Fundación Marqués de Valdecilla and Fundación Mutua Madrileña. LA-R was supported by a grant for Research Aid from Wyeth Pharma (Spain).

  • Competing interests None.

  • Ethics approval All the patients and controls gave signed informed consent and the study was approved by the regional ethics committee.

  • Provenance and Peer review Not commissioned; externally peer reviewed.

This Article

  1. All Versions of this Article:
    1. ard.2008.103663v1
    2. 69/01/263 most recent

Services

  1. Request permissions

Responses

  1. Submit a response
  2. No responses published

Social bookmarking

Register for free content


Free sample
This recent issue is free to all users to allow everyone the opportunity to see the full scope and typical content of ARD.
View free sample issue >>

Free archive
The full back archive is now available for Annals of the Rheumatic Diseases. Institutional subscribers may access the entire archive as part of their subscription. Personal subscribers will also have access to all content when logged in. Non-subscribers who register have free access to all articles published before 2006, back to volume 1 issue 1.
Register to access the free archive >>

Don't forget to sign up for content alerts so you keep up to date with all the articles as they are published.

  • Latest Rheumatology Jobs

    Rheumatology Jobs